Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of radium-223 plus exemestane and everolimus versus placebo plus exemestane and everolimus in hormone receptor-positive, HER2-negative metastatic breast cancer with bone metastases
MOH_2017-03-14_000028Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Radium-223 dichloride + exemestane + everolimus with Placebo + exemestane + everolimus (2 arms). Primary endpoint: Symptomatic skeletal event-free survival. Started Oct 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-03-14_000028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000028.